Bioventus (BVS) Competitors $7.14 +0.29 (+4.29%) As of 07/3/2025 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BVS vs. NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, TNDM, ESTA, and LQDAShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors NovoCure LeMaitre Vascular National Vision Enovis CONMED Artivion Cadre Tandem Diabetes Care Establishment Labs Liquidia Technologies Bioventus (NYSE:BVS) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Is BVS or NVCR more profitable? Bioventus has a net margin of -7.11% compared to NovoCure's net margin of -26.41%. Bioventus' return on equity of 15.61% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% NovoCure -26.41%-45.46%-13.34% Which has more risk and volatility, BVS or NVCR? Bioventus has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Does the media refer more to BVS or NVCR? In the previous week, NovoCure had 7 more articles in the media than Bioventus. MarketBeat recorded 7 mentions for NovoCure and 0 mentions for Bioventus. NovoCure's average media sentiment score of 0.39 beat Bioventus' score of 0.00 indicating that NovoCure is being referred to more favorably in the news media. Company Overall Sentiment Bioventus Neutral NovoCure Neutral Do institutionals & insiders believe in BVS or NVCR? 62.9% of Bioventus shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 5.5% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend BVS or NVCR? Bioventus presently has a consensus price target of $14.33, indicating a potential upside of 100.63%. NovoCure has a consensus price target of $32.83, indicating a potential upside of 85.45%. Given Bioventus' higher possible upside, analysts clearly believe Bioventus is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable valuation and earnings, BVS or NVCR? Bioventus has higher earnings, but lower revenue than NovoCure. Bioventus is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$567.70M1.03-$156.23M-$0.48-14.88NovoCure$605.22M3.26-$168.63M-$1.51-11.73 SummaryBioventus beats NovoCure on 9 of the 15 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$586.84M$255.90M$5.53B$20.72BDividend YieldN/AN/A5.24%3.72%P/E Ratio-11.715.9227.5228.09Price / Sales1.0373.84421.0238.30Price / Cash12.58196.1236.8922.53Price / Book2.556.128.044.58Net Income-$156.23M-$27.18M$3.18B$986.06M7 Day Performance5.52%0.42%2.90%2.79%1 Month Performance9.74%-7.17%3.70%5.46%1 Year Performance22.54%25.54%36.15%15.06% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus2.7289 of 5 stars$7.14+4.3%$14.33+100.6%+21.3%$586.84M$567.70M-11.711,200Positive NewsNVCRNovoCure3.6878 of 5 stars$17.80-1.1%$32.83+84.5%+4.9%$2.01B$605.22M0.001,488LMATLeMaitre Vascular2.7158 of 5 stars$83.05+0.6%$97.83+17.8%+3.8%$1.87B$219.86M41.70490Positive NewsEYENational Vision2.652 of 5 stars$23.01-0.7%$18.67-18.9%+92.2%$1.83B$1.82B64.3613,411Positive NewsENOVEnovis3.549 of 5 stars$31.36-1.3%$58.00+84.9%-24.3%$1.82B$2.11B10.127,367Positive NewsCNMDCONMED4.6557 of 5 stars$52.10-0.1%$62.20+19.4%-19.5%$1.61B$1.31B12.083,900Positive NewsAORTArtivion2.4992 of 5 stars$31.17-0.1%$32.00+2.7%+18.8%$1.33B$388.54M124.761,600CDRECadre3.6812 of 5 stars$31.94-0.3%$37.50+17.4%-5.3%$1.30B$567.56M33.722,284TNDMTandem Diabetes Care4.2181 of 5 stars$18.64-1.6%$33.43+79.3%-57.1%$1.26B$940.20M0.002,650Positive NewsESTAEstablishment Labs1.3905 of 5 stars$42.71+4.3%$52.40+22.7%+0.4%$1.18B$166.02M0.001,018LQDALiquidia Technologies3.2403 of 5 stars$12.46-4.9%$26.89+115.8%+2.4%$1.12B$14M0.0050Positive News Related Companies and Tools Related Companies NovoCure Alternatives LeMaitre Vascular Alternatives National Vision Alternatives Enovis Alternatives CONMED Alternatives Artivion Alternatives Cadre Alternatives Tandem Diabetes Care Alternatives Establishment Labs Alternatives Liquidia Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BVS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BVS Stock Alerts